AIMS/HYPOTHESIS: We hypothesised that type 1 @entity6 patients with established @entity3949 ( @entity3949 ) would @entity1347 in comparison to healthy age-matched controls. We aimed to investigate the co-relationships between gastrointestinal function, degree of @entity3949 and clinical symptoms. METHODS: An observational comparison was made between 48 patients with @entity3949 (39 men, mean age 50  years, range 29-71  years), representing the baseline data of an ongoing clinical trial (representing a secondary analysis of baseline data collected from an ongoing double-blind randomised controlled trial investigating the neuroprotective effects of liraglutide) and 41 healthy participants (16 men, mean age 49  years, range 30-78) who underwent a standardised wireless motility capsule test to assess gastrointestinal transit. In patients, vibration thresholds, the Michigan Neuropathy Screening Instrument and Patient Assessment of Upper Gastrointestinal Symptom questionnaires were recorded. RESULTS: Compared with healthy controls, patients showed prolonged gastric emptying (299        289 vs 179        49  min; p   =   0.01), small bowel transit (289        107 vs 224        63  min; p   =   0.001), colonic transit (2140, interquartile range [IQR] 1149-2799  min vs 1087, IQR 882-1650  min; p   =   0.0001) and whole-gut transit time (2721, IQR 1196-3541  min vs 1475 (IQR 1278-2214) min; p   <   0.0001). Patients also showed an increased fall in pH across the ileocaecal junction (-1.8        0.4 vs -1.3        0.4 pH; p   <   0.0001), which was associated with prolonged colonic transit (r   =   0.3, p   =   0.001). Multivariable regression, controlling for sex, disease duration and glycaemic control, demonstrated an association between whole-gut transit time and total GCSI (p   =   0.02). CONCLUSIONS/INTERPRETATION: Pan-enteric prolongation of gastrointestinal transit times and a more acidic caecal pH, which may represent heightened caecal fermentation, are present in patients with type 1 @entity6 . The potential implication of delayed gastrointestinal transit on the bioavailability of nutrition and on pharmacotherapeutic and glycaemic control warrants further investigation. TRIAL REGISTRATION: EUDRA CT: 2013-004375-12.

Type 1 XXXX patients with peripheral neuropathy have pan-enteric prolongation of gastrointestinal transit times and an altered caecal pH profile.

@entity1347 :: ('MESH:C537775', 'Disease') :: ['have segmental and/or pan-enteric dysmotility'] @entity3949 :: ('MESH:D003929', 'Disease') :: ['diabetic sensorimotor polyneuropathy', 'DSPN'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes']
@entity6 :: (MESH:D003920,Disease) :: ['diabetic']
